Impact BioMedical Reports Going Concern Audit Opinion, Continues Merger Plans

The biotech firm's 2025 annual report included a 'going concern' qualification from its auditor, but it's still moving forward with a planned merger.

Apr. 3, 2026 at 6:19pm

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of medical documents, a calculator, and a pen arranged on a clean white background, conceptually representing the financial challenges facing the biopharmaceutical company.As Impact BioMedical navigates financial uncertainty, its planned merger faces new scrutiny from investors and regulators.Houston Today

Impact BioMedical Inc. announced that its 2025 annual report filed in March 2026 included an audit opinion from Grassi & Co., CPAs, P.C. that contained a 'going concern' qualification. The company said this announcement does not represent any change or amendment to its 2025 financial statements. Separately, Impact Biomedical continues with strategic plans to merge with Dr. Ashley's Ltd., projected to be completed by July 1, 2026.

Why it matters

The 'going concern' audit opinion raises questions about Impact BioMedical's financial stability and ability to continue operations, which could impact the proposed merger with Dr. Ashley's. However, the company is moving forward with the merger plans, suggesting it believes the deal could help address the auditor's concerns.

The details

Impact BioMedical's 2025 annual report, filed on March 11, 2026, included an audit opinion from Grassi & Co., CPAs, P.C. that contained a 'going concern' qualification. This means the auditor has substantial doubt about the company's ability to continue as a going concern. The company said this announcement does not represent any change or amendment to its 2025 financial statements.

  • Impact BioMedical filed its 2025 annual report on March 11, 2026.
  • The company plans to complete its merger with Dr. Ashley's Ltd. by July 1, 2026.

The players

Impact BioMedical Inc.

A biopharmaceutical and consumer healthcare company that discovers and patents new technologies.

Grassi & Co., CPAs, P.C.

The auditing firm that issued the 'going concern' qualification in Impact BioMedical's 2025 annual report.

Dr. Ashley's Ltd.

The company that Impact BioMedical plans to merge with by July 1, 2026.

Got photos? Submit your photos here. ›

What they’re saying

“This announcement does not represent any change or amendment to the Company's financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2025.”

— Impact BioMedical Inc.

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

The 'going concern' audit opinion raises concerns about Impact BioMedical's financial stability, but the company is moving forward with plans to merge with Dr. Ashley's Ltd. in an apparent effort to address those issues. The outcome of the merger could have significant implications for the company's future.